IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the phase III study is to investigate whether IMA901 can prolong
overall survival in patients with metastatic and/or locally advanced renal cell carcinoma
(RCC) when added to standard first-line therapy with sunitinib.
Secondary objectives include a subgroup analysis of overall survival in patients defined by a
certain biomarker signature, the investigation of progression-free survival, best tumor
response, safety, and immunological parameters.